Interim results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with PEG-IFNα in patients with chronic HBV/HDV co-infection

Conference Reports for NATAP

The Liver Meeting
San Francisco
November 2018


Interim results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with PEG-IFNα in patients with chronic HBV/HDV co-infection

	Reported by Jules Levin AASLD 2018 Nov 9-13 SF